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Background: DNA copy number variants (CNVs) are found in 15% of subjects with ID but their association with
phenotypic abnormalities has been predominantly studied in smaller cohorts of subjects with detailed yet
non-systematically categorized phenotypes, or larger cohorts (thousands of cases) with smaller number of
generalized phenotypes.
Methods: We evaluated the association of de novo, familial and common CNVs detected in 78 ID subjects with
phenotypic abnormalities classified using the Winter-Baraitser Dysmorphology Database (WBDD) (formerly the
London Dysmorphology Database). Terminology for 34 primary (coarse) and 169 secondary (fine) phenotype
features were used to categorize the abnormal phenotypes and determine the prevalence of each phenotype in
patients grouped by the type of CNV they had.
Results: In our cohort more than 50% of cases had abnormalities in primary categories related to head (cranium,
forehead, ears, eye globes, eye associated structures, nose) as well as hands and feet. The median number of
primary and secondary abnormalities was 12 and 18 per subject, respectively, indicating that the cohort consisted
of subjects with a high number of phenotypic abnormalities (median De Vries score for the cohort was 5).
The prevalence of each phenotypic abnormality was comparable in patients with de novo or familial CNVs in
comparison to those with only common CNVs, although a trend for increased frequency of cranial and forehead
abnormalities was noted in subjects with rare de novo and familial CNVs. Two clusters of subjects were identified
based on the prevalence of each fine phenotypic feature, with an average of 28.3 and 13.5 abnormal
phenotypes/subject in the two clusters respectively (P < 0.05).
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Conclusions: Our study is a rare example of using standardized, deep morphologic phenotype clustering with
phenotype/CNV correlation in a cohort of subjects with ID. The composition of the cohort inevitably influences the
phenotype/genotype association, and our studies show that the influence of the de novo CNVs on the phenotype
is less obvious in cohorts consisting of subjects with a high number of phenotypic abnormalities. The outcome of
phenotype/genotype analysis also depends on the choice of phenotypes assessed and standardized phenotyping
is required to minimize variability.
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phenotypesBackground
Intellectual disability (ID) has an overall prevalence of 1–
3% [1,2] and is characterized by considerable genetic and
phenotypic heterogeneity. Single gene and chromosomal
disorders are considered the cause of ID in 7–37% of cases
[3], while submicroscopic gains and losses (DNA copy
number variants (CNVs)) occur in a further 5–15% of cases
[4,5]. Screening for CNVs using chromosome microarrays
is now routinely performed in subjects with ID and data-
bases of CNVs identified in subjects with ID or controls fa-
cilitate CNV interpretation (e.g. Database of Chromosomal
Imbalance and Phenotype in Human Using Ensemble Re-
sources, DECIPHER, http://decipher.sanger.ac.uk/, or Data-
base of Genomic Variants, DGV, http://projects.tcag.ca/
variation, respectively).
The association of unique CNVs with congenital and
neurodevelopmental abnormalities has been documented
in reports on individual subjects, small groups of similarly
affected subjects (for review see [6]) or large cohorts of pa-
tients [7-11]. Large cohort studies including thousands of
cases have the benefit of assessing the overall characteris-
tics of CNVs (e.g. size, burden) and their influence on
phenotype; however, typically, they lack detailed clinical
descriptions, with the phenotype derived from referral
forms for array testing, rather than from a detailed chart
review. Nevertheless, these studies are informative and
show that large CNVs (>400 Kb) harboring more genes
(i.e. large CNV burden) are more prevalent in cases with
more severe developmental phenotypes associated with
multiple congenital anomalies (MCA) [7], including cra-
niofacial dysmorphology and cardiac defects, compared to
ID without MCA [7,8].
Thus far, the association of the CNV presence/charac-
teristics with a more detailed and systematic clinical de-
scription of a larger number of subjects has been rarely
performed. Moreover, the various phenotypes selected
for analysis mainly are based on a-priori expectations of
phenotypes likely to be affected by chromosomal gain or
loss. In a pioneering study, De Vries et al. investigated
the association of 21 clinical features in 29 and 110 ID
subjects with and without subtelomeric region copy
number changes, respectively and introduced a five itemchecklist (i.e. de Vries Score) to help select ID patients
most likely to have submicroscopic subtelomeric rear-
rangements (family history of ID, prenatal-onset growth
retardation, postnatal growth abnormalities, ≥2 facial dys-
morphic features, and congenital anomalies). Using this
checklist the authors reported a significant correlation of
prenatal onset of growth retardation and a positive family
history with subtelomeric abnormalities [12].
In contrast, a recent study of >300 ID cases showed that
pathogenic CNVs are significantly correlated with con-
genital heart anomalies among the 23 clinical features ana-
lyzed [13]. Prevalence of microcephaly, short stature and
low weight was also higher in cases with pathogenic
CNVs, but did not reach statistical significance when com-
pared to cases without pathogenic CNVs. In our previous
study of 100 cases with autism spectrum disorder (ASD)
and ID [14], in which 10 major phenotypes were evalu-
ated, we reported significant prevalence of microcephaly
in cases with pathogenic CNVs and a more severe cogni-
tive deficit in comparison to ASD/ID subjects with normal
array results [14].
The most recent study correlating CNV types and phe-
notypes used Human Phenotype Ontology, HPO based
standardized phenotyping in a cohort of >5000 ID patients
[15]. However, although 34,433 HPO phenotypic features
were evaluated the prevalence of only 9 “lumped” features
was assesses and reported in different CNV classes (de
novo, inherited and no rare CNVs). Significantly increased
frequency for 7 out the 9 abnormal features was identified
(Multiple congenital anomalies, Dysmorphism, Stature,
Convulsions, Head circumference, Brain, Heart, Urogenital)
in subjects with de novo CNVs. The patients were also
assessed using a modified de Vries Score which included
intellectual disability, prenatal onset of growth retardation,
postnatal growth abnormalities, ≥2 dysmorphic facial fea-
tures and congenital anomalies. A significant prevalence
of subjects with >3 De Vries score in both the de novo
and familial CNV groups in comparison to no rare CNV
group was noted in their cohort which had an overall me-
dian De Vries score of 2.
Our study was designed to evaluate the association of
different types of CNVs and phenotypes found in 78
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Database (WBDD) (formerly the London Dysmorphology
Database) (http://www.lmdatabases.com/about_lmd.html)
and is to our knowledge the first study using this database
for CNV/phenotype correlation analysis. It is also unique
because the information on the prevalence of each indi-
vidually detailed primary and secondary phenotype in sub-
jects with de novo, familial and common CNVs was
recorded, compared and reported. The patients were also
clustered based on the phenotypes and the prevalence of
each phenotypic feature in each cluster was assessed.
Methods
Subjects
A total of 78 subjects with ID were included in the analysis,
recruited through a network of collaborating clinical geneti-
cists from centers across Canada. The criteria for recruit-
ment were based on the previously published De Vries
score of 3 or higher, which resulted in enrolment of pre-
dominantly complex cases with an unknown etiology of ID.
Phenotypes were collected from patient charts and con-
firmed by a clinical geneticist and a genetic counsellor for
categorical standardization. This subset of patients was
chosen based on: a) the use of array platform of similar
resolution for analysis (NimbleGen and Agilent); b) avail-
ability of detailed clinical information c) previously normal
karyotype and Fragile X screening. As controls we used a
previously published cohort of 32 cognitively and phenotyp-
ically normal subjects (19 females and 13 males) analyzed
using the same array platform [16,17]. The use of the DNA
from these patients in our cohort was approved by Clinical
Ethics Research Board, University of British Columbia. All
subjects gave written informed consent for participation in
the study and anonymized data were used for the analysis.
Array comparative genomic hybridization (CGH)
Agilent 105 K oligonucleotide array-CGH analysis was per-
formed according to the protocol provided by the company
(version 4.0, June 2006, Agilent Technologies, CA, USA)
[18]. Feature Extraction software (version 8.1.1.1, Agilent
Technologies) rendered image analysis using the manufac-
turer’s recommended settings (CGH_v4_95) and human
genome assembly hg18. The minimum absolute average of
log2 ratio was 0.25. Higher-resolution 385 K oligonucleo-
tide genome array CGH was performed by courtesy of
NimbleGen. Array log2 ratio > ±0.2 was used for segmen-
tation (region). For both the Agilent and NimbelGen array
platforms, 3 consecutive probes were required for a signifi-
cant CNV call. CNVs from all chromosomes were included
in the analysis.
Type of CNVs
All detected CNVs were grouped into 3 subgroups (de
novo, familial and common CNVs) based on criteriondescribed previously [19]. Briefly, CNVs completely
overlapping with variants reported in at least two stud-
ies in the DGV or in our internal controls consisting of
cognitively normal subjects [16,17] were considered
common CNVs; CNVs that overlapped partially (<50%)
or did not overlap with CNVs reported in the DGV or
our internal controls were called unique (rare) CNVs
and these included de novo and familial CNVs. All
unique CNVs were confirmed and their origin (paren-
tal or de novo) determined by a secondary independent
method (FISH or qPCR) on available cell pellet or
DNA. Common CNVs from DGV v10 for hg18 have
been downloaded at http://projects.tcag.ca/variation/
tableview.asp?table=DGV_Content_Summary.txt. The
database contained 67694 common CNVs at the time of
analysis.Clinical feature classification
The Winter-Baraitser Dysmorphology Database (WBDD)
(formerly the London Dysmorphology Database) (http://
www.lmdatabases.com/about_lmd.html) was used to sys-
tematically categorize the phenotypes of each patient in
our cohort. WBDD consists of 34 major clinical features
as the primary category, 162 features in the secondary
category and numerous further sub-classifications in the
tertiary category. We used the primary and secondary
categories of WBDD (named as coarse and fine pheno-
types, respectively) to classify the phenotypes of our pa-
tients. We also slightly modified WBDD by adding
Microcephaly and Macrocephaly as secondary categor-
ies within the Cranium-primary category (they are listed
in the WBDD tertiary category). We also added the fol-
lowing features as separate items in the secondary cat-
egory: Family history, abnormal pregnancy history,
neonatal abnormality, maternal age at birth and pater-
nal age at birth. This resulted in 169 fine phenotypic
features.
For our analysis, clinical features that were present in
less than 5% (i.e. in less than 4 individuals) or over 95%
(i.e. in more than 74 individuals) were excluded. We
eventually included 32 coarse phenotypes (after remov-
ing Neurology and Pelvis categories with 78/78 and 2/
78 individuals, respectively) in the primary category
and 80 fine phenotypes in the secondary category. The
complete list of coarse and fine phenotypes is presented in
Additional file 1: Table S1. The process of phenotype col-
lection from chart review was extremely time-consuming,
and to systematically collect the information, we used
RedCap (https://cric.med.ualberta.ca/neurodevnet/) [20]
for both the phenotype and CNV data storage and ex-
traction. It not only shortened our data processing time,
but also minimized any mistakes that might be induced
in the process.
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Computing
All computational analysis was done using software R 2.12
for Windows (The R Project for Statistical computing:
http://www.R-681project.org) [21]. Fisher’s exact test was
used in comparisons of equality of proportions. CNV size
comparison was performed using the Wilcoxon rank-sum
test.
Prevalence of clinical features in subjects with different CNV
types
Subjects were classified in groups based on the type of
CNV present (de novo, familial or common). We com-
puted the fraction of each abnormal phenotypic feature
in these groups and tested the significance of the differ-
ence in the prevalence of each of the phenotypes be-
tween subjects with de novo versus common CNVs, and
familial versus common CNVs using Fisher’s exact test
(corrected for multiple tests using the Benjamini and
Hochberg procedure) [22].
Clustering
We performed a k-means clustering based on a list of
80 fine clinical features. The optimal value for K (num-
ber of clusters) was chosen using the Calinski index
[23], which represents the ratio of the variance within
the clusters and the variance between the clusters. It is
similar to an F (ANOVA) statistic. This was performedFigure 1 Data processing workflow.by the cascade KM function from the R package vegan
2.0–7 [24].Results
Characterization of CNVs in subjects with idiopathic ID
The workflow of our study is shown in Figure 1. Using
whole genome oligonucleotide microarrays (Agilent 105 K
and NimbleGen 385 K), 527 CNVs were identified in 78
subjects with idiopathic ID (on average 7 CNVs/person).
CNVs were classified into three subgroups based on the
criteria described in Methods. Twenty-one unique de novo
CNVs, 27 unique familial CNVs and 479 common CNVs
were identified in the ID cohort (Table 1 and Additional
file 1: Table S2). De novo CNVs ranged in size from 310
Kb to 9.7 Mb (2.5 Mb median) and were significantly lar-
ger than common CNVs (0.1 Mb median) (p = 2.3 × 10-11,
Wilcoxon’s rank-sum test). The proportion of duplications
and deletions was similar among the categories except for
familial CNVs, for which 70% of cases were duplications
(p = 0.002, as determined by the rank-sum test compared
to pooled de novo and common CNVs). The proportion of
deletions (and thus also duplications) in the common
CNVs is similar to that observed in DGV, 59% vs. 64%, re-
spectively. We also examined the overall gene content of
the different classes of CNVs. For the purpose of our ana-
lysis, genes within 50 Kb of the estimated CNV break-
points were included. Significantly more genes were found
Table 1 CNV features comparison in different CNV types
Common CNVs Familial CNVs De novo CNVs Overall for the cohort
Number of CNVs 479 27 21 527
Patients 78 22 18 78
CNVs/subject 6.14 1.23 1.17 6.77
Mean CNV size (Mb) 0.42 0.70 3.14 0.54
Median CNVs size (Mb) 0.14 0.43 2.46 0.14
Range of CNV size (Mb) 0.01–9.68 0.03–4.36 0.31–9.78 0.01–9.78
Genes/CNV 5.12 7.04 33.1 6.34
Proportion of large CNVs (>1 Mb) 0.14 0.22 0.71 0.17
Proportion of deletion 0.59 0.30 0.67 0.58
Median modified De Vries Score 5 4.5 5 5
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expected based on the size difference (Table 1).
Six de novo CNVs and 5 familial CNVs overlapped
with syndromic regions previously described in the DE-
CIPHER database (Additional file 1: Table S2). Eighteen
of our cases carried de novo CNVs (23%), with one case
(5%) encompassing two independent de novo CNVs
(2q23.3 deletion and 10q21.1 deletion) (Additional file 1:
Table S2). The slightly higher prevalence of de novo
CNVs in comparison to the literature could be the effect
of enrolment criteria which was based on De Vries scor-
ing system and typically included more phenotypically
complex cases. In the unique familial CNV group, 3/22
cases (13%) have 2–3 familial CNVs. There are 2 cases
having both a de novo and a familial CNV.
Clinical phenotypes classification
Patient records including detailed consult letters were
reviewed to categorize the clinical information in 34
coarse and 169 fine clinical features for each subject,
using the Winter-Baraitser Dysmorphology Database
(WBDD) (www.lmdatabases.com/about_lmd.htm) (Additional
file 1: Table S1). The phenotypic categories were slightly
modified (see Methods for details) by removing from ana-
lysis non-varying phenotypes (e.g. present or absent in
more than 95% of the subjects). In addition, we included
categories such as prenatal and family history (see
Methods for details), and obtained a working set of 80
“fine” phenotypes within 32 “coarse” categories corre-
sponding to the WBDD ontology. The median number of
coarse and fine abnormalities was 12 and 18 per subject,
respectively.
Other than the neurology class (100%), the most
prevalent phenotypes in our cohort, present in >50% of
cases, were abnormalities of the head, such as abnormal-
ities of the cranium (72%), ears (68%), eyes (67%) and
nose (64%), as well as abnormalities of hands (69%) and
feet (65%) (Figure 2, Additional file 1: Table S1). The
median De Vries Score (Vulto-van Silfhout et al. [15])was used to ascertain the severity of phenotypes in our co-
hort. Seventy-five out of 78 cases (96%) have a score ≥3
and the median De Vries score of the whole cohort is 5.
Phenotype/genotype analysis
CNV type/phenotype data for all patients individually
are presented in Additional file 1: Table S3. To explore
the relationship between the abnormal phenotypes and
presence of de novo, familial and common CNVs we ex-
amined for patients in the 3 CNV groups the median
number of coarse and fine abnormalities, the modified
de Vries score and the prevalence of each phenotypic
feature. We also compared the median de Vries score in
subjects with deletions and duplications. Finally, pres-
ence of patterns of CNV/phenotype associations for the
whole cohort was explored using clustering analysis.
The median number of coarse abnormalities in sub-
groups of patients with de novo, familial, and common
CNVs was 12.5, 10.5, and 14.5 while for fine phenotypes, it
was 17.5, 14.5, and 19 for each sub-group, respectively. The
modified De Vries score was 5, 4.5 and 5 for sub-groups
with de novo CNVs, unique familial and common CNVs,
respectively. No statistically significant difference was found
for the prevalence of any of the phenotypes in different
CNV groups after corrections for multiple tests (Fisher’s
exact test, corrected for multiple tests). However, our data
showed that among the phenotypes present in >20% of
cases, abnormalities of the forehead and cranium were
more prevalent in subjects with de novo than common
CNVs (Figure 3). When 80 fine phenotypes were con-
sidered, abnormalities of forehead (i.e., shape, height,
prominence etc.), of brain (structural anomalies), deaf-
ness (conductive and sensorineural) and macrocephaly
(OFC >98%) were more prevalent in cases with de novo
than with common CNVs, although this was not signifi-
cant after multiple test corrections (Additional file 2:
Figure S1).
Similarly, a higher prevalence of forehead anomalies
was noted in subjects with familial CNVs when coarse
Figure 2 Prevalence of abnormal coarse phenotypes. Thirty-four coarse phenotypes were evaluated among our 78 patients based on WBDD
criteria (see Additional file 1: Table S1 for the whole term of each phenotype). *indicates phenotype with >95% or <5% prevalence in the cohort
which was removed in the statistical analysis.
Figure 3 Phenotype and de novo CNV association analysis. Prevalence of the abnormality of each of the coarse phenotypes in individuals
with de novo CNVs (18 cases) compared to individuals with only common CNVs (40 cases). The phenotypes with a prevalence >95% or <5% in
the whole cohort (78 cases) were excluded from calculation.
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notypes were considered, number of cases with family his-
tory of ID, and with forehead anomalies was higher in the
familial than common CNV group, and muscle abnormal-
ities were seen in ~5 times more cases with familial CNVs.
However, these frequencies did not reach significant levels
after corrections for multiple tests (Additional file 3:
Figure S2). The type of CNV (deletion or duplication)
slightly affected the severity of the phenotype based on
the modified De Vries score (score of 5.5 for deletions
and 4.6 for duplications).
Finally, to explore the association of clinical pheno-
types with CNV subtypes more generally, K-means clus-
tering analysis was performed on patients based on the
80 fine phenotypes. The optimal number of clusters was
computationally determined to be two (see Methods).
Individuals belonging to the first cluster had significantly
more phenotypic abnormalities (mean 28.3/subject) than
those from the second cluster (mean 13.5/subject; p =
2.7 × 10-12; Wilcoxon rank-sum test) (Figure 5). 24 out
of 80 phenotypes were significantly more prevalent in
cluster 1 compared to cluster 2 (P < 0.05, Fisher’s exact
test after multiple test correction) (Figure 5 and Additional
file 1: Table S4). We stress that differences in phenotypes
between the clusters are expected since the clustering is
based on the phenotypes. However, neither the number of
total CNVs, the number of de novo or familial CNVs, nor
CNV size segregated with the clusters.Figure 4 Phenotype and familial CNV association analysis. Prevalence
cases) compared with those containing only common CNVs (40 cases). Tw
the analysis. The phenotypes with a prevalence >95% or <5% in the wholeDiscussion
This report contributes a unique exploration of the asso-
ciation of detailed phenotypic categories applied from
the LDD with de novo, familial and common CNV sub-
types, to systematically record, compare and report pri-
mary and secondary phenotypic abnormalities in 78 ID
subjects. Our cohort consisted of subjects with a high
number of phenotypic abnormalities with a median of
12 for primary and 18 for secondary features/subject.
This was also reflected in a high median modified De
Vries score of 5 for the whole cohort. We did not detect
significant prevalence for any of the phenotypes in sub-
jects with unique de novo or familial CNVs in compari-
son to those with common CNVs only, and it is possible
that the high and comparable severity of the phenotype
in three CNV subgroups in our cohort eliminated the
CNV impact. Nevertheless, we noted higher prevalence
of several abnormalities in the unique (de novo and fa-
milial) CNV subgroup in comparison to the common
CNV subgroup (e.g. forehead abnormalities) while in
subjects with only common CNVs, abnormalities of skin
and thorax were present almost 2 times more frequently
than in subjects with de novo or familial CNVs.
There are very few previous studies that correlate 10 ~
23 phenotypic features in subjects with ID with the pres-
ence or absence of submicroscopic genomic changes. No
consistent results were found among these studies regard-
ing the specific phenotypes significantly prevalent in eachof abnormal coarse phenotypes in individuals with familial CNVs (20
o individuals with both de novo and familial CNVs were removed from
cohort (78 cases) were excluded from calculation.
Figure 5 Clustering of individuals based on 80 fine phenotypes. (A) Data displayed as heat map. K-means method was used to group the
78 individuals into two clusters. The filled dark squares indicate an abnormal phenotype. Statistically significant differences in the number of
phenotype abnormalities were found between the two clusters (P < 0.05, Wilcoxon rank-sum test). The different groups of CNVs in each individual
are indicated at the top of the heat map. (B) Data displayed as barplot. The prevalence of individuals with an abnormal phenotype was compared
between the two clusters. *indicates P < 0.05 (Fisher exact test after multiple test corrections).
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dence of prenatal abnormalities and positive family history
of ID in children with subtelomeric abnormalities than in
patients without subtelomeric defects [12], while our pre-
vious study of ASD/ID subjects [14] noted that microceph-
aly and severity of ID were more significantly present in
cases with pathogenic CNVs in comparison to cases with-
out pathogenic CNVs. More recently, significantly higher
prevalence of heart abnormalities in ID subjects with clin-
ically relevant CNVs or chromosome abnormalities, was
noted by Shoukier et al. [13], while statistical difference in
the prevalence of microcephaly and short stature was not
reported between the groups. Of note, higher prevalence
of macrocephaly, epilepsy and short stature was reported
in subjects with pathogenic CNVs. The most recent study
by Vulto-van Silfhout et al. identified facial dysmorphism,
abnormal head circumference, central nervous system
anomalies, heart anomalies, urogenital anomalies and
modified De Vries scores ≥3 to occur at significantlyhigher frequency in subjects with de novo CNVs based on
assessment of >5000 subjects phenotyped using HPO.
Possible reasons for discrepancy between studies include
selection biases in ID subjects that had array testing (study
cohorts). For example our cohort had a median de Vries
score of 5, while for the cohort of Vulto-van Silfhout et al.
the median score was 2. In addition, differences in the
classification of CNVs exist between studies; for example
Shoukier et al. included as pathogenic CNVs large scale
chromosome abnormalities and syndromic and familial
CNVs, while Vulto-van Silfhout excluded syndromic CNVs
caused by LCRs and divided the patients based on pres-
ence of rare de novo, familial or no rare CNVs. Finally, dif-
ferences in available/recorded phenotypic characteristics
of patient cohorts, differences in the selection of clinical
features being evaluated, or the discrepancy in the strin-
gency or type of statistical methods used for data analysis,
could be the cause of variable genotype/phenotype associ-
ations. In our study, the clinical information was obtained
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scription preferences of each of the participating clinical
geneticists, and these also could influence the findings.
Ideally, the use of a relevant and standardized ontology
classification of phenotypes derived from deep phenotyp-
ing initiatives will improve phenotype/genotype analyses
relevant to scientific discovery and personalized patient
management of genomic causes of ID.
The WBDD database catalogues phenotypes systematic-
ally by annotation of anatomic regions and systems for the
human body. Only the primary and secondary phenotype
categories with more concise descriptors were used in our
study, to avoid the overwhelming detail of tertiary category
designations (mostly absent from patient records). The
WBDD is user-friendly and easy to master, with the defin-
ition for most of the symptoms provided by the database.
However, in our consideration of specific characteristics of
patients with ID phenotypes, we found the database pre-
sented some limitations. For example, it does not include
prenatal information, family history, severity of ID (by IQ
or adaptive/functional measures), all of which could offer
essential elements of the phenotype in the context of ID.
Similarly, some phenotypes commonly described in prac-
tice, such as motor delays (oral, fine, gross motor), cranio-
facial dysmorphism, microcephaly and macrocephaly,
are not listed as isolated items in primary or secondary
categories. In addition, the best match for ID is neur-
ology in the primary category, which contains three
secondary features: behaviour, learning disabilities and
neuro-abnormalities. The WBDD also contains an ex-
tended number of features that are rarely reported in ID
within the primary categories such as pelvis, voice and
skeletal system. A directly targeted, separate, and sys-
tematic ontology system for accurate and comprehen-
sive ID phenotypic designations would be beneficial for
achieving more accurate phenotype/genotype correl-
ation and clinical translation. This system should have a
detailed description of neurodevelopmental features,
considering the prevalence of cranial abnormalities in
our cohort.
CNVs are only one of the possible sources of genomic
variation that can be pathogenic in ID [4,5]. With the
advent of whole exome or genome sequencing tech-
niques, novel sequence mutations have been found to
play important role in the pathogenesis of ID in cases
with or without detected pathogenic CNVs [25-28]. Our
clustering analysis allowed us to group subjects in two
clusters based on frequencies of abnormalities (median
28 or 13 per subject) and it will be interest to explore
the mutation types and frequencies in these two groups
of patients in the future. Establishing the functional con-
sequences of gene copy number or sequence changes is
also important for the assessment of their impact on the
phenotype and studies addressing closer functional andphenomic linkages are becoming more common [29-33].
Efforts to use a more standardized and detailed pheno-
typing system in combination with array-CGH, sequen-
cing and gene functional analysis is needed to improve
our understanding of phenotype/genotype correlations
and optimize their translation into accurate genetic
counselling.
Conclusions
Our study uniquely explores the association of de novo, fa-
milial and common CNV subtypes with detailed pheno-
types categorized by a commonly used human phenome
ontology database. Our cohort consisted of cases with a
high median number of phenotypic abnormalities in all
CNV subgroups which possibly resulted in no significant
difference in the frequency of any of the studied phe-
notypes between the CNV sub-groups. Nevertheless, our
study provides a detailed comprehensive and systematic
cross-section of the frequencies of primary and secondary
phenotypes in CNV sub-groups based on WBDD. We
found WBDD to be user-friendly and easy to master with
the definition for most of the symptoms provided by the
database. Wider use of standardized and detailed pheno-
typing systems in combination with current whole genome
analyses, including chromosome arrays and whole genome
sequencing, is needed for achieving more accurate pheno-
type/genotype correlation and clinical translation.
Additional files
Additional file 1: Table S1. WBDD phenotype frequency in our cohort.
Table S2 De novo and familial CNVs detected in the cohort (hg18). Table
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